Century Therapeutics Stock Performance
| IPSC Stock | USD 2.42 0.11 4.76% |
Century Therapeutics holds a performance score of 22 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.53, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Century Therapeutics will likely underperform. Use Century Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Century Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Century Therapeutics are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Century Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 49.3 M | |
| Total Cashflows From Investing Activities | 47.5 M |
Century Therapeutics Relative Risk vs. Return Landscape
If you would invest 60.00 in Century Therapeutics on October 25, 2025 and sell it today you would earn a total of 182.00 from holding Century Therapeutics or generate 303.33% return on investment over 90 days. Century Therapeutics is currently generating 2.7065% in daily expected returns and assumes 9.505% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Century, and 46% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Century Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Century Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Century Therapeutics, and traders can use it to determine the average amount a Century Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Century Therapeutics is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Century Therapeutics by adding it to a well-diversified portfolio.
Century Therapeutics Fundamentals Growth
Century Stock prices reflect investors' perceptions of the future prospects and financial health of Century Therapeutics, and Century Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Century Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0447 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 91.83 M | ||||
| Shares Outstanding | 87.41 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 1.78 X | ||||
| Revenue | 6.59 M | ||||
| EBITDA | (111.47 M) | ||||
| Cash And Equivalents | 378.76 M | ||||
| Cash Per Share | 6.43 X | ||||
| Total Debt | 53.83 M | ||||
| Debt To Equity | 0.12 % | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (110.14 M) | ||||
| Earnings Per Share | (0.32) X | ||||
| Total Asset | 353.22 M | ||||
| Retained Earnings | (782.34 M) | ||||
About Century Therapeutics Performance
By analyzing Century Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Century Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Century Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Century Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. Century Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 170 people.Things to note about Century Therapeutics performance evaluation
Checking the ongoing alerts about Century Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Century Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Century Therapeutics is way too risky over 90 days horizon | |
| Century Therapeutics appears to be risky and price may revert if volatility continues | |
| Century Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with profit before overhead, payroll, taxes, and interest of 7.99 M. | |
| Century Therapeutics currently holds about 378.76 M in cash with (110.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 75.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Why Medicus Pharma Ltd. stock could rally in 2025 - GDP Growth Short-Term High Return Strategies - ulpravda.ru |
- Analyzing Century Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Century Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Century Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Century Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Century Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Century Therapeutics' stock. These opinions can provide insight into Century Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |